Life expectancy among HIV-positive patients in Rwanda: a retrospective observational cohort study (Q41377430)

30 September 2017

Life expectancy among HIV-positive patients in Rwanda: a retrospective observational cohort study (English)

1 reference

30 September 2017

0 references

0 references

8

Agnes Binagwaho

1 reference

30 September 2017

1

Sabin Nsanzimana

0 references

Steve Kanters

3

object named as

Steve Kanters

0 references

Edward J. Mills

9

object named as

Edward J Mills

1 reference

30 September 2017

6

Nathan Ford

1 reference

30 September 2017

Eric Remera

2

1 reference

30 September 2017

Steve Kanters

3

1 reference

30 September 2017

Keith Chan

4

1 reference

30 September 2017

Jamie I Forrest

5

1 reference

30 September 2017

Jeanine Condo

7

1 reference

30 September 2017

1 March 2015

1 reference

30 September 2017

The Lancet Global Health

1 reference

30 September 2017

3

1 reference

30 September 2017

3

1 reference

30 September 2017

e169-77

1 reference

There and back again: the impact of adult HIV prevalence on national life expectancies

30 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2814%2970364-X

7 January 2021

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2814%2970364-X

7 January 2021

Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2814%2970364-X

7 January 2021

Rwanda 20 years on: investing in life

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2814%2970364-X

7 January 2021

The 2013 WHO guidelines for antiretroviral therapy: evidence-based recommendations to face new epidemic realities

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2814%2970364-X

7 January 2021

Evaluation of methodologies for small area life expectancy estimation

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2814%2970364-X

7 January 2021

Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2814%2970364-X

7 January 2021

Correcting mortality for loss to follow-up: a nomogram applied to antiretroviral treatment programmes in sub-Saharan Africa

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2814%2970364-X

7 January 2021

Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2814%2970364-X

7 January 2021

Potential years of life lost between ages 1 and 70: an indicator of premature mortality for health planning

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2814%2970364-X

7 January 2021

Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2814%2970364-X

7 January 2021

Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2814%2970364-X

7 January 2021

Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2814%2970364-X

7 January 2021

Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2814%2970364-X

7 January 2021

Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2814%2970364-X

7 January 2021

When to start antiretroviral therapy: the need for an evidence base during early HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2814%2970364-X

7 January 2021

When to start ART in Africa--an urgent research priority

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2814%2970364-X

7 January 2021

Prevention of HIV-1 infection with early antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2814%2970364-X

7 January 2021

Integration of antiretroviral therapy with tuberculosis treatment

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2814%2970364-X

7 January 2021

The future role of CD4 cell count for monitoring antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2814%2970364-X

7 January 2021

Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2814%2970364-X

7 January 2021

10.1016/S2214-109X(14)70364-X

Identifiers

DOI

1 reference

30 September 2017

1 reference